The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults.

Autor: Liebisch-Rey H; Evidence-Based Therapeutics Group, Department of Clinical Pharmacology, Faculty of Medicine, Universidad de La Sabana and Clinica Universidad de La Sabana, Chía, Cundinamarca, 140013, Colombia., Suarez-Chacon AM; Evidence-Based Therapeutics Group, Department of Clinical Pharmacology, Faculty of Medicine, Universidad de La Sabana and Clinica Universidad de La Sabana, Chía, Cundinamarca, 140013, Colombia., Fuentes YV; Evidence-Based Therapeutics Group, Department of Clinical Pharmacology, Faculty of Medicine, Universidad de La Sabana and Clinica Universidad de La Sabana, Chía, Cundinamarca, 140013, Colombia., Blanco J; Evidence-Based Therapeutics Group, Department of Clinical Pharmacology, Faculty of Medicine, Universidad de La Sabana and Clinica Universidad de La Sabana, Chía, Cundinamarca, 140013, Colombia., Kock J; Department of Epidemiology, Faculty of Medicine, Universidad de La Sabana, Chía, Cundinamarca, 140013, Colombia., Lechtig-Wassermann S; Evidence-Based Therapeutics Group, Department of Clinical Pharmacology, Faculty of Medicine, Universidad de La Sabana and Clinica Universidad de La Sabana, Chía, Cundinamarca, 140013, Colombia., Bustos RH; Evidence-Based Therapeutics Group, Department of Clinical Pharmacology, Faculty of Medicine, Universidad de La Sabana and Clinica Universidad de La Sabana, Chía, Cundinamarca, 140013, Colombia.

Publikováno v: F1000Research [F1000Res] 2023 Dec 11; Vol. 12, pp. 914. Date of Electronic Publication: 2023 Dec 11 (Print Publication: 2023).